Merck’s Covid-19 Antiviral Pill Can Reduce Hospitalization Risk by 50%
Merck’s experimental drug known as molnupiravir, for the purpose of treating severe novel corona virus patients has been successful in decreasing the risk of hospitalization and deaths of the people by around 50 percent in the results of the interim clinical trials. The molnupiravir tablet had been given two times a day to the patients […]
Continue Reading